Oct 2007Acne
Patient Preference Study Comparing Two Clindamycin / Benzoyl Peroxide Gels...
Source: Clinicalstudyresults.org

Patient Preference Study Comparing Two Clindamycin / Benzoyl Peroxide Gels

This was a multicenter study conducted by qualified investigators at 2 clinical sites in the U.S. 30 patients were planned to be enrolled at each site (total of 60 patients). View Trial (PDF )

Aug 2001Alcohol Dependency
A Phase Ib Evaluation of the Safety and Pharmacokinetics of Repeat Dose......
Source: Clinicalstudyresults.org

A Phase Ib Evaluation of the Safety and Pharmacokinetics of Repeat Dose Administration of Medisorb® Naltrexone in Alcohol Dependent Patients

This was a multi-center, randomized, double-blind, placebo-controlled, study in which DSM IV alcohol dependent subjects received an IM injection of study drug every 28 days. A total of 4 injections were administered over the course of the study. Subjects received either Medisorb Naltrexone (400 mg) or placebo. Treatments were randomly assigned in a 5:1 (active:placebo) ratio. Psychosocial support was offered to subjects in both treatment groups; US sites used the BRENDA approach, European sites used the best common practice. View Trial (PDF )

May 2005Alzheimers
Late Phase II Study for BPSD (Behavioral and Psychological Symptoms of Dementia)......
Source: Clinicalstudyresults.org

Late Phase II Study for BPSD (Behavioral and Psychological Symptoms of Dementia) in Patients with Alzheimer’s Disease.

Late phase II clinical study of FK949 (Quetiapine fumarate) for psychiatric symptoms and behavioral disorders in patients with Alzheimer’s dementia-Double-blind, placebo-controlled, parallel-group, dose-finding study View Trial (PDF )

May 2005Anemia
An open label, randomized, multi-center, multiple dose trial to investigate the efficacy......
Source: Roche- Clinical Trails Results

An open label, randomized, multi-center, multiple dose trial to investigate the efficacy and safety of subcutaneous injections of Mircera at different dosing intervals in patients with chronic renal anemia who are not on renal replacement therapy.

This was an open, randomized, multicenter, dose escalation study investigating the effect of 3 doses of Mircera (methoxy polyethylene glycol-epoetin beta) and 3 different dosing intervals on renal anemia in patients not on dialysis. View Trial (Web )

Aug 2007Anemia
An open-label, randomized, multicenter trial investigating the efficacy and safety of once weekly......
Source: Centerwatch

An open-label, randomized, multicenter trial investigating the efficacy and safety of once weekly (reduced administration frequency) NeoRecormon therapy versus thrice weekly NeoRecormon therapy in anemic patients with metastatic solid tumors (breast, lung, colorectal, ovarian, cervical and prostate cancer) receiving chemotherapy (or scheduled to receive chemotherapy) for at least 9 weeks.

This was an open-label, randomized, multicenter, two arm study to investigate weekly NeoRecormon therapy, compared to thrice weekly NeoRecormon therapy, in anemic patients receiving chemotherapy (or scheduled to receive chemotherapy). The study was prematurely terminated, following regulatory approval of the once-weekly dosing regimen. View Trial (Web )

Mar 2007Anemia
Comparative, monocenter, randomized, single-blind, cross-over study in healthy volunteers comparing local pain......
Source: Centerwatch

Comparative, monocenter, randomized, single-blind, cross-over study in healthy volunteers comparing local pain after subcutaneous injection of epoetin beta (NeoRecormon®) versus darbepoetin alfa (Aranesp®).

This was a comparative, randomized, single-blind, cross-over study comparing local pain experienced after subcutaneous injections of NeoRecormon versus darbepoetin alfa. View Trial (Web )

Jun 2005Arthritis
A Multicenter, Randomized, Parallel-Group, 4-Week, Double-Blind and Active Comparator-Controlled Study to Assess the Efficacy,......
Source: Clinicalstudyresults.org

A Multicenter, Randomized, Parallel-Group, 4-Week, Double-Blind and Active Comparator-Controlled Study to Assess the Efficacy, Safety and Tolerability of MK-0663 Tablet 60 mg Once Daily Versus Diclofenac Sodium 75 mg Two Times Daily In the Treatment of Chinese Patients with Osteoarthritis of the Knee or Hip (PN 080; NCT00140972)

A Multicenter, Randomized, Parallel-Group, 4-Week, Double-Blind and Active Comparator-Controlled Study to Assess the Efficacy, Safety and Tolerability of MK-0663 Tablet 60 mg Once Daily Versus Diclofenac Sodium 75 mg Two Times Daily In the Treatment of Chinese Patients with Osteoarthritis of the Knee or Hip. View Trial (PDF )

Oct 2003Arthritis
A Randomized, Double-Blind, Multicenter Comparison of the Effects of Celecoxib 200 mg BID......
Source: Clinicalstudyresults.org

A Randomized, Double-Blind, Multicenter Comparison of the Effects of Celecoxib 200 mg BID Versus Rofecoxib 25 mg QD and Dietary Sodium on Blood Pressure in Osteoarthritis (OA) Subjects With Treated Systolic Hypertension

Primary: To compare the effects of celecoxib 200 mg twice a day (BID) to rofecoxib 25 mg once daily (QD) on 24-hour systolic blood pressure (SBP) as measured by ambulatory blood pressure monitoring (ABPM) with varying dietary sodium intake in systolic hypertensive OA patients treated with an angiotensin-converting enzyme (ACE) inhibitor, a beta-blocker and/or an angiotensin II receptor antagonist View Trial (PDF )

Jul 2001Arthritis
A Double-Blind, Placebo-Controlled, Randomized Six Week Comparison Study of the Efficacy of Celecoxib......
Source: Clinicalstudyresults.org

A Double-Blind, Placebo-Controlled, Randomized Six Week Comparison Study of the Efficacy of Celecoxib 200 mg QD and Rofecoxib 25 mg QD in Relieving the Signs and Symptoms of Osteoarthritis of the Knee

Primary objective: To compare the efficacy of celecoxib, rofecoxib, and placebo in relieving the signs and symptoms of a flare of osteoarthritis (OA) of the knee. View Trial (PDF )

Nov 2002Arthritis
A Double-Blind, Randomized, Three Arm, Two Period, Crossover Study to Compare Celecoxib, Acetaminophen,......
Source: Clinicalstudyresults.org

A Double-Blind, Randomized, Three Arm, Two Period, Crossover Study to Compare Celecoxib, Acetaminophen, and Placebo in Patients with Osteoarthritis of the Hip or Knee

The primary objective of this study was to evaluate the efficacy and safety of celecoxib, acetaminophen, and placebo in a randomized, double-blind, crossover clinical trial in ambulatory patients with osteoarthritis (OA) of the hip or knee. View Trial (PDF )

Jan 2005Arthritis
A randomized, multifactorial, double-blind, parallel-group, dose-ranging study of the efficacy and safety......
Source: Roche- Clinical Trails Results

A randomized, multifactorial, double-blind, parallel-group, dose-ranging study of the efficacy and safety of rituximab (MabThera/Rituxan) in combination with methotrexate in patients with active rheumatoid arthritis.

This randomized, double-blind, double-dummy, controlled, multifactorial study evaluated nine different treatment regimens in a 3 x 3 configuration, comprising three different dose levels of MabThera (rituximab) (including placebo) and three different corticosteroid regimens (including placebo), along with methotrexate (MTX), and folate. Approximately 40 RF-positive patients were enrolled into each of the nine possible combinations. View Trial (Web )

Jul 2005Asthma
A comparative study of inhaled ciclesonide 160 μg/day vs budesonide 400 μg/day......
Source: Clinicalstudyresults.org

A comparative study of inhaled ciclesonide 160 μg/day vs budesonide 400 μg/day in patients with asthma

To compare the effect of 160 μg ciclesonide/day with 400 μg budesonide/day on lung function, symptoms and use of rescue medication including the onset of effect in patients with bronchial asthma View Trial (PDF )

Feb 2008Bone Cancer
Experimental Drug for Osteosarcoma Improves Overall Survival...
Source: National Cancer Institute

Experimental Drug for Osteosarcoma Improves Overall Survival

The study - conducted by the Children's Oncology Group - was the largest final-stage randomized trial in this disease and included 662 patients with newly diagnosed nonmetastatic osteosarcoma. View Trial (Web )

Mar 2007Brain cancer
Palliative Radiation Extends Survival for Elderly Patients with Glioblastoma...
Source: National Cancer Institute

Palliative Radiation Extends Survival for Elderly Patients with Glioblastoma

The investigators enrolled 81 patients 70 years of age or older with glioblastoma into the trial. All patients had good functional status. Forty-two received supportive care alone, including antiseizure medication, physical and psychological support, and access to a palliative care team. The other 39 patients received supportive care and radiation therapy (50 Gy in doses of 1.8 Gy per day, given 5 days a week). View Trial (Web )

Mar 2008Breast Cancer
Paclitaxel Versus Docetaxel for Early Breast Cancer...
Source: National Cancer Institute

Paclitaxel Versus Docetaxel for Early Breast Cancer

In a study comparing different dosing schedules of two common breast cancer drugs, weekly treatment with the drug paclitaxel (Taxol) in addition to standard chemotherapy proved most effective in extending overall survival and disease-free survival among women with early-stage breast cancer. Treatment with the drug docetaxel (Taxotere) every three weeks improved patients’ disease-free survival and is also an acceptable choice. View Trial (Web )

Mar 2008Breast Cancer
Anastrozole, Tamoxifen, and Bone Loss on the ATAC Trial...
Source: National Cancer Institute

Anastrozole, Tamoxifen, and Bone Loss on the ATAC Trial

Postmenopausal women taking the drug anastrozole (Arimidex®) to prevent a recurrence of breast cancer suffered more bone loss than women taking tamoxifen (Nolvadex®), even while anastrozole provided better protection against relapse, according to a substudy of a major clinical trial comparing the two drugs. Doctors and patients need to consider all risks and benefits when deciding on the best adjuvant approach for women with hormone-positive, early-stage breast cancer. View Trial (Web )

Aug 2007Breast Cancer
Boost Radiation Beneficial in Early-Stage Breast Cancer...
Source: National Cancer Institute

Boost Radiation Beneficial in Early-Stage Breast Cancer

In women with early-stage breast cancer who had been treated with breast-conserving lumpectomy and radiation, an additional “boost” dose of radiation to the original tumor site reduced the risk of cancer coming back in the same breast, though it did not help them live longer. View Trial (Web )

Jun 2007Breast Cancer
Heart Problems From Trastuzumab (Herceptin®) Do Not Increase in the Short Term...
Source: National Cancer Institute

Heart Problems From Trastuzumab (Herceptin®) Do Not Increase in the Short Term

It’s known that women with HER2-positive breast cancer who take the drug trastuzumab (Herceptin®) in addition to chemotherapy are at greater risk of heart problems during treatment. Now a study has shown that the incidence of such problems does not increase in the short term and that many women regain heart health after an initial decline. However, the long-term effects of trastuzumab on the heart remain to be determined. View Trial (Web )

Jan 2007Breast Cancer
Study Confirms Risk of Bone Loss for Patients Taking Exemestane...
Source: National Cancer Institute

Study Confirms Risk of Bone Loss for Patients Taking Exemestane

Women who switched to the drug exemestane (Aromasin®) after taking tamoxifen (Nolvadex®) to prevent a breast cancer relapse lost more bone density and had a higher risk of bone fractures than women who continued taking tamoxifen, an international study has concluded. View Trial (Web )

Jun 2006Breast Cancer
Whole Brain Radiation May be Postponed in Cancer Patients with Limited Metastasis......
Source: National Cancer Institute

Whole Brain Radiation May be Postponed in Cancer Patients with Limited Metastasis to the Brain

Patients who received stereotactic radiosurgery for four or fewer contained metastases to the brain lived as long, and had comparable radiation side effects and mental functioning, as patients who were also treated with whole brain radiation. However, the radiosurgery-only patients had higher recurrence in their brain and were more likely to require salvage treatment. View Trial (Web )